What’s New from La Roche-Posay in 2022?

Join us for a 60 minute webinar on two unique topics that impact the health and beauty of the skin:

Photoprotection Update – How COVID-19 and Working from Home Changed Sun Safe Behaviors

Neal Bhatia, MD, FAAD
Director of Clinical Dermatology
Therapeutics Clinical Research


Cosmeceuticals for Preventative and Restorative Aging

Patricia Farris, MD, FAAD
Sanova Dermatology
Metairie, LA




Watch Video

What’s New from La Roche-Posay?

Managing Dry Skin Conditions, Including Atopic Dermatitis

Dr. Peter Lio will discuss common factors that lead to dry skin, including various forms of eczema. Dr. Lio will will share clinical data and features and benefits of the new and improved La Roche-Posay Lipikar Balm AP+M, featuring the patented ingredient Microresyl, which can help prevent biofilm formation.

Managing Hyperpigmentation and the Role of OTC

Dr. Kavita Mariwalla will give an overview on how she manages hyperpigmentation in her practice as well as provide an overview on the clinical data and features and benefits of La Roche-Posay Glycolic B5 Serum. This lightweight formula is suitable for multiple skin tones, helps reduce the look of dark spots and discolorations and reveals brighter, more even looking skin. This serum combines concentrated 10% pure glycolic acid, tranexamic acid (TXA), lipo-hydroxy acid, and vitamin B5 for optimal effectiveness while also being suitable for sensitive skin.


Peter Lio, MD, FAAD

Assistant Professor of Clinical Dermatology and Pediatrics
Northwestern University, Feinberg School of Medicine
Chicago, Illinois

Kavita Mariwalla, MD, FAAD

Mariwalla Dermatology






Watch Video

Skincare for Cancer Patients and Survivors: US Cutaneous Oncodermatology Management (USCOM) – A Practical Algorithm


The US Cutaneous Oncodermatology Management (USCOM) project aims to improve cancer patients’ and survivors’ quality of life by offering tools for preventing and managing cancer treatment-related cutaneous toxicities.

The USCOM panel of clinicians who treat cancer treatment-related cutaneous CAEs developed, discussed, and reached a consensus on statements and an evidence-based algorithm supporting prevention, treatment, and maintenance using OTC skincare measures. The algorithm focuses on skincare measures to prevent and treat cutaneous toxicities using prevention measures and a skincare regimen involving hygiene, moisturization, sun protection, and camouflage products. The algorithm aims to improve patient outcomes and sought to determine the best approach for oncology skincare programs for all stakeholders in the US health care setting. These include medical oncologists, family practice/internal medicine physicians, dermatologists, oncology nurses, advanced practice providers (APPs), nurse practitioners (NP), physician assistants (PA), and pharmacists.


Mario Lacouture, MD, FAAD 
Onco-Dermatology Program
Memorial Sloan Kettering Cancer Center
Professor, Dermatology
Weill Cornell Medicine
New York, New York


Alice Ho, MD, MBA 
Radiation Oncologist
Massachusetts General Hospital
Associate Professor
Harvard Medical School
Director of Breast Radiation Oncology
Boston, Massachusetts








Watch Video

Practicing Dermatology Today: What You Need to Know

Join us for a special two-part webinar on timely dermatology topics that include Q&A!

Mona Gohara, MD
Associate Clinical Professor
Department of Dermatology
Yale School Of Medicine
Angelo Landriscina, MD
Site Director for Dermatology
Mount Sinai Doctors-Brooklyn Heights
Brooklyn, NY


Supported by La Roche-Posay 

Click here for bio
Watch Video

ODOMZO® (sonidegib): a non-surgical option for patients with locally advanced BCC – ON DEMAND WEBINAR

Sponsored by Sun Pharmaceuticals

This promotional event is sponsored by Sun Pharmaceutical Industries, Inc. The speaker is a paid consultant presenting on behalf of Sun Pharmaceutical Industries, Inc


Come learn about ODOMZO, a non-surgical option for patients with locally advanced basal cell carcinoma, and have a discussion with Dr. Daniel M. Siegel, MD, FAAD, FACMS. This program will discuss the use of ODOMZO in the current COVID-19 setting, and will provide useful information about treating laBCC lesions that are located in sensitive areas, when multiple lesions are present, or when small lesions recur in the same location.
ODOMZO (sonidegib) is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.
Daniel M. Siegel, MD, FAAD, FACMS
Clinical Professor of Dermatology
State University of New York
Health Sciences Center at Brooklyn
Brooklyn, NY

Dr. Daniel Siegel is Clinical Professor of Dermatology at the State University of New York (SUNY) Health Sciences Center at Brooklyn in New York. He is also a
dermatologist in private practice at Long Island Skin Cancer and Dermatologic Surgery in Smithtown, New York. Dr. Siegel is board certified in dermatology and laser surgery, and is a certified professional coder in dermatology. He was head of the Division of Dermatologic Surgery at SUNY Stony Brook for 12 years. Dr Siegel has authored more than 100 articles in peer-reviewed journals, as well as numerous books and book chapters. He currently serves as Editor of eMedicine Dermatology, sits on the editorial board of Ostomy Wound Management, and is a reviewer for numerous journals. Dr. Siegel is a Fellow and Past President of the American Academy of Dermatology. He is also a Fellow of the American College of Mohs Surgery, the American Society for Dermatologic Surgery, and the American Society for Mohs Surgery. A five-time recipient of the American Academy of Dermatology’s Presidential Citation, Dr Siegel has been listed in Castle Connolly’s “Top Long Island Doctors” for the past 9 years.
Watch Video